Novel Therapies for Treating Familial Hypercholesterolemia
- 575 Downloads
Familial hypercholesterolemia is an inherited disorder associated with early accelerated atherosclerosis with morbidity and mortality resulting from premature cardiovascular disease. Affected individuals have extreme elevations in low-density lipoprotein cholesterol levels. Patients usually do not achieve target reductions in cholesterol levels with conventional antihyperlipidemic pharmacotherapy. This unmet need has resulted in the recent development and approval of novel therapies targeting different cholesterol pathways. This article briefly summarizes familial hypercholesterolemia and then discusses the newer pharmacotherapies available in the management of familial hypercholesterolemia.
KeywordsFamilial hypercholesterolemia Mipomersen Proprotein convertase subtilisin/kexin 9 inhibitors Lomitapide
Salim S. Virani is supported by a Department of Veterans Affairs Health Services Research and Development Service Career Development Award.
Conflict of Interest
Salman J. Bandeali, Jad Daye, and Salim S. Virani declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of outstanding importance
- 3.Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Sly WS, Childs B, Beaudet AL, Valle C, Kinzler KW, Vogelstein B, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 2863–913.Google Scholar
- 7.Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3):133–40.PubMedCrossRefGoogle Scholar
- 8.Widhalm K, Binder CB, Kreissl A, Aldover-Macasaet E, Fritsch M, Kroisboeck S, et al. Sudden death in a 4-year-old boy: a near-complete occlusion of the coronary artery caused by an aggressive low-density lipoprotein receptor mutation (W556R) in homozygous familial hypercholesterolemia. J Pediatr. 2011;158(1):167.PubMedCrossRefGoogle Scholar
- 9.Smith RJ, Hiatt WR. Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder. JAMA Intern Med. 2013;6:1–3.Google Scholar
- 12.Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013. doi: 10.1093/eurheartj/eht273.Google Scholar
- 14.••Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40–6. This was the first phase 3 dose-escalation study that evaluated the efficacy and safety of lomitapide in HoFH patients. The beneficial results of the study led to the FDA approval for lomitapide..PubMedCrossRefGoogle Scholar
- 20.Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29–36.PubMedCrossRefGoogle Scholar
- 21.Stein EA, Ose L, Retterstol K, Tonstad S, Schleman M, Harris S, et al. Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. J Clin Lipidol. 2007;1(4):280–6.PubMedCrossRefGoogle Scholar
- 23.US Food and Drug Administration. FDA approves new orphan drug for rare cholesterol disorder. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm 2012.
- 24.Aegerion Pharmaceuticals. FDA approves Aegerion Pharmaceuticals’ JUXTAPID(TM) (lomitapide) capsules for homozygous familial hypercholesterolemia (HoFH). http://ir.aegerion.com/releasedetail.cfm?ReleaseID=728650 2012.
- 25.••Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998–1006. This reports a phase 3 trial showing the effect of mipomersen on lowering LDL-C levels in HoFH patients..PubMedCrossRefGoogle Scholar
- 26.••McGowan MP, Tardif JC, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7(11):e49006. This reports a randomized placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia that showed an increase in cardiovascular incidents in the mipomersen arm..PubMedCentralPubMedCrossRefGoogle Scholar
- 27.Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126(19):2283–92.PubMedCrossRefGoogle Scholar
- 29.•Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UH, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33(9):1142–9. This reports a randomized double-blind placebo-controlled study of mipomersen in statin-intolerant patients with high risk of cardiovascular disease..PubMedCrossRefGoogle Scholar
- 30.US Food and Drug Administration. KYNAMRO (mipomersen sodium) injection. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203568s000lbl.pdf.
- 31.•Genzyme. A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol (FOCUS FH). 2011–2013. Available from http://clinicaltrials.gov/show/NCT01475825. This is a randomized placebo-controlled trial currently being done to determine the effect of mipomersen in severe HeFH.
- 32.••Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12):1108–18. This reported a phase 1 trial of PCSK9-inhibiting monoclonal antibody (REGN727) showing a significant decrease in LDL-C levels in blood of HeFH patients..PubMedCrossRefGoogle Scholar
- 45.•Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman D, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60(19):1888–98. This reported a phase 1 study that evaluated the safety and effects of AMG145 (PCSK9 antibody) in healthy and hypercholesterolemic subjects receiving statin therapy..PubMedCrossRefGoogle Scholar
- 46.••Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126(20):2408–17. This reported a multicenter, phase 2 randomized trial that tested the safety and efficacy of AMG145 (PCSK9 antibody) in HeFH patients already receiving intensive antihyperlipidemic therapy..PubMedCrossRefGoogle Scholar
- 47.•Amgen. Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities (TESLA). 2012–2013. Available from http://www.clinicaltrials.gov/ct2/show/NCT01588496?term=TESLA&rank=3. This is a multicenter randomized trial that is currently being done to test the safety and efficacy of AMG145 (PCSK9 antibody) in HoFH patients.